Dongrui Ray Lu
Dongrui Ray Lu publishes mostly in Oncology, Pulmonary and Respiratory Medicine and Cancer Research, on topics such as Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research and Cancer-related Molecular Pathways.
- World rank
- #227,856 of 7,710,434 ranked researchers
- Rank in United States
- #84,142 of 1,627,098
- Works
- 96
- Citations
- 10k
- Citations per work
- 107.8
What does Dongrui Ray Lu research?
Dongrui Ray Lu's work is mostly in Medicine (63%), Biochemistry, Genetics and Molecular Biology (18%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences6163.2%
- Medicine6163.2%
- Everything else1819.1%
- Life Sciences1717.7%
- 1Oncology32% of their works
- 2Pulmonary and Respiratory Medicine26% of their works
- 3Cancer Research10% of their works
- 4Molecular Biology8% of their works
- 5Epidemiology3% of their works
- 6Radiology, Nuclear Medicine and Imaging2% of their works
Research topics
Which keywords describe Dongrui Ray Lu's research?
The keywords of their largest research topics: Breast Cancer, Metastatic Breast Cancer, CDK4/6 Inhibitors, Palbociclib, Chemotherapy, Survival Analysis, HER2 and Trastuzumab.
- Pancreatic Neuroendocrine Tumors
- Neuroendocrine Tumors
- Small-Cell Lung Cancer
- Taxanes
- Gene Expression
- p53
- Trastuzumab
- Survival Analysis
- Palbociclib
- Metastatic Breast Cancer
- Breast Cancer
- CDK4/6 Inhibitors
- Chemotherapy
- HER2
- Cell Cycle
- Breast Tumours
- Chemotherapy-Induced Peripheral Neuropathy
- Genomic Profiles
- BET Bromodomains
- PROTACs
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 20 words, with their numbers
- Breast Cancer872 topics
- Metastatic Breast Cancer712 topics
- CDK4/6 Inhibitors601 topic
- Palbociclib601 topic
- Chemotherapy372 topics
- Survival Analysis282 topics
- HER2271 topic
- Trastuzumab271 topic
- Cell Cycle241 topic
- p53241 topic
- Breast Tumours211 topic
- Gene Expression211 topic
- Chemotherapy-Induced Peripheral Neuropathy111 topic
- Taxanes111 topic
- Genomic Profiles101 topic
- Small-Cell Lung Cancer101 topic
- BET Bromodomains71 topic
- Neuroendocrine Tumors71 topic
- PROTACs71 topic
- Pancreatic Neuroendocrine Tumors71 topic
Where does Dongrui Ray Lu work?
Dongrui Ray Lu's main affiliation in the publication record is Pfizer (United States), United States.
How many publications and citations does Dongrui Ray Lu have?
OpenAlex counts 96 works and 10,346 citations for Dongrui Ray Lu, an h-index of 31, ranking #227,856 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Dongrui Ray Lu. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.